Overview
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
Description
In this study the investigator would like to better understand the use of high-dose rate (HDR) brachytherapy to target only recurrent prostate cancer that can be seen by AXUMIN PET scan. The use of HDR brachytherapy for prostate cancer is not new, but it is a more recent advancement to use it to treat only what can be seen instead of the whole prostate.
Eligibility
Inclusion Criteria:
History of histologically confirmed, clinically localized adenocarcinoma of the prostate
treated with external beam radiation, brachytherapy, or combination of external beam
radiation and brachytherapy, with curative intent completed at least 24 months ago F-18
fluciclovine (AXUMIN) PET scan within 90 days prior to registration demonstrating recurrent
lesion within the prostate gland Biopsy confirmation of disease recurrence within the
prostate gland Age ≥ 18 KPS ≥ 70% Suitable candidate for brachytherapy based on established
criteria IPSS score <16 No pelvic arch interference No Rectal fistula/fissure Fit for
general or spinal anesthesia No history of urethral stricture Ability to understand, and
willingness to sign the written informed consent
Exclusion Criteria:
Evidence of metastatic or nodal disease outside of the prostate gland on AXUMIN PET scan
within 90 days prior to enrollment Patient unable to have MRI Patients with neuroendocrine
or small cell carcinoma of the prostate TURP within 6 months prior to enrollment History of
Crohn's disease, ulcerative colitis, or known radiation proctitis Inability to understand
spoken and written English
